E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002274 |
E.1.2 | Term | Anemia aplastic |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess the safety and tolerability of REGN7257 in patients with severe aplastic anemia (SAA) that is refractory to or has relapsed while on standard of care immunosuppressive therapy (IST). An additional primary objective (for Part B only) is to evaluate the clinical efficacy of REGN7257 in IST-refractory/ relapsed patients. |
|
E.2.2 | Secondary objectives of the trial |
- Clinical response over time
- Maintenance of response
- Impact on transfusion requirements
- Effect on blood counts and cell populations
- Pharmacokinetics (PK)
- Immunogenicity |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
1: Future Biomedical Research sub-study:
Patients who agree to participate in the future biomedical research sub-study will be required to
consent to this optional sub-study before samples are banked in long-term storage. Additional
samples will be collected for future biomedical research according to time points listed in the
Schedule of Events (Table 1 and Table 2). The unused biomarker samples for study-related
research, the unused PK and ADA samples, as well as the samples collected for future biomedical
research, will be stored for up to 15 years after the final date of the database lock. The unused
samples may be utilized for future biomedical research.
2: Pharmacogenomic Analysis sub-study:
The purpose of the pharmacogenomic analyses is to identify genomic associations with clinical or
biomarker response to REGN7257, other aplastic anemia clinical outcome measures and possible
AEs. |
|
E.3 | Principal inclusion criteria |
1. SAA that is refractory to or has relapsed while on standard of care IST, as defined in the protocol
2. Hematopoietic stem cell transplantation (HSCT) is not available or suitable as a treatment option or has been refused by the patient
3. Adequate hepatic and renal function as defined in the protocol
Other protocol-defined inclusion criteria apply |
|
E.4 | Principal exclusion criteria |
1. Diagnosis of Fanconi anemia as defined in the protocol
2. Evidence of myelodysplastic syndrome as defined in the protocol
3. Paroxysmal nocturnal hemoglobinuria (PNH) with evidence of significant hemolysis or history of PNH-associated thrombosis
4. Treatment with a T cell-depleting agent (eg, ATG or alemtuzumab) within 6 months prior to dosing
5. Treatment with a calcineurin inhibitor (eg, cyclosporine) within 4 weeks prior to dosing
6. Treatment with eltrombopag or investigational thrombopoietin receptor agonist, Granulocyte Colony-Stimulating Factor (G-CSF), or an androgen (eg, danazol), within 2 weeks prior to dosing
7. HIV, hepatitis B or hepatitis C positive by serological testing at the screening visit
8. Active tuberculosis, latent tuberculosis infection (LTBI) or history incompletely-treated tuberculosis or LTBI
Other protocol-defined exclusion criteria apply |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Part A
- Incidence of adverse events (AEs); 12 months post-treatment, approximately 52 weeks
Parts A and B
- Incidence of serious adverse events (SAEs); 12 months post-treatment, approximately 52 weeks
- Incidence and severity of treatment-emergent adverse events (TEAEs); 12 months post-treatment, approximately 52 weeks
Part B
- Overall response rate (ORR); 6 months post-treatment, approximately 26 weeks |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Parts A and B
ORR; 3 months post-treatment, approximately 12 weeks
Complete response (CR); 3 months post-treatment, approximately 12 weeks
Partial response (PR); 3 months post-treatment, approximately 12 weeks
Time to best response; Up to 12 months
Time to first response; Up to 12 months
Proportion of patients who maintain any clinical response; Up to 12 months
Platelet transfusions per month over time; Up to 12 months
Red blood cell transfusions per month over time; Up to 12 months
Changes in lymphocyte cell counts; Up to 12 months
Changes in neutrophil cell counts; Up to 12 months
Changes in hemoglobin cell counts; Up to 12 months
Changes in reticulocyte cell counts; Up to 12 months
Changes in platelet cell counts; Up to 12 months
Changes in the whole blood immune cell subsets (T cells); Up to 12 months
Changes in the whole blood immune cell subsets (B cells); Up to 12 months
Changes in the whole blood immune cell subsets (NK cells); Up to 12 months
Drug concentrations in serum over time; Up to 12 months
Incidence of treatment-emergent anti-drug antibody (ADA) over time; Up to 12 months |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity and Tolerability |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Korea, Republic of |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |